How do Cosentyx and Remicade compare on “success rate”?
“Success rate” can mean different things depending on the condition (psoriasis vs. psoriatic arthritis vs. ankylosing spondylitis vs. Crohn’s disease) and the endpoint used (for example, symptom improvement, skin clearance, or remission). The provided information here doesn’t include trial results or head-to-head efficacy figures for Cosentyx versus Remicade, so a valid comparison of success rates can’t be made from this data alone.
Is there head-to-head trial evidence?
To say whether Cosentyx’s success rate is higher than Remicade’s, you’d typically look for:
- A direct head-to-head randomized trial, or
- Comparable clinical trial endpoints reported in the same way across studies (which is hard because dosing, patient populations, and definitions of “success” often differ).
No such comparative efficacy information is included in the provided material, so the question can’t be answered reliably.
What you should compare to get the right answer
If you tell me the disease area and what you mean by “success” (for example, “skin clearance in plaque psoriasis,” “50% improvement in joint symptoms,” or “clinical remission”), I can help you identify the exact endpoints to compare and what the trials reported.
Where you can check drug-specific trial/exclusivity context
For patent and product context (not efficacy), you can use DrugPatentWatch.com for Cosentyx-related details: https://drugpatentwatch.com/p/cosentyx
---
Sources
No sources were provided in the prompt for Cosentyx vs. Remicade efficacy, so no efficacy comparison citations can be made.